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Background: The development of mixed chimerism/graft
rejection is not uncommon following transplant for FA. A
proportion of children with FA demonstrate somatic mosai-
cism, carrying two populations of lymphocytes, one with
a true DEB sensitive phenotype, and a second population of
lymphocytes with a DEB resistant phenotype, often arising
from a somatic gene conversion event in compound hetero-
zygous cells, generating a single normal FA allele. Preparative
regimens for FA transplants are typically dose-reduced to
accommodate the increased toxicity associated with the FA
phenotype, andwhile sufﬁcient to clear lymphocytes with anTable 1
Patient, Donor and Transplant Characteristics and Results
Patient
characteristics
Age range (years) 8 to 13
Donor
characteristics
Patient 1 MURD (7/8)
Patient 2 MURD (8/8)
Patient 3
Transplant # 1 MSD (7/8)
Transplant # 2 MMRD (6/8
parent)
Transplant
characteristics
Graft T-cell depleted, CD34 selected PBSC graft,
GVHD prophylaxis CSA
Results
Patient 1 Day + 9 Day + 14 Day + 30 Day + 5
ALC 110 470 2180
Donor chimerism % 100 100 65
Alemtuzumab
Patient 2
ALC 570 860 540 4000
Donor chimerism % 99.6 98 97 69
Alemtuzumab
Patient 3 Day + 12 Day + 19 Day + 30 Day + 3
Transplant #1 ALC 0 60 100 980
Donor chimerism % 100 99.2 98.8 62.8
Alemtuzumab
Day + 9 Day + 14 Day + 16 Day + 1
Transplant #2 ALC 10 50 1260 1260
Donor chimerism % 100 98 85 89
AlemtuzumabFA phenotype, may not be adequate for revertant or mosaic
lymphocytes with a revertant or mosaic phenotype. We
describe a series of three children with FA who received
Alemtuzumab for treatment of mixed chimerism associated
with an abrupt rise in their absolute lymphocyte count (ALC),
likely due to expansion of host lymphocyte populations with
a DEB resistant mosaic phenotype.
Methods: Patients, donor and transplant characteristics are
shown in Table 1. Conditioning regimen included busulfan
0.8-1.0 mg/kg/dose Q 12hrs (with pharmacokinetic
monitoring) x 4 doses, ﬂudarabine 35 mg/m2/dose,
cyclophosphamide 10 mg/Kg/dose, and ATG 2.5 mg/kg/dose
once daily x 4 doses.
Results: After initial complete engraftment, each child dis-
played an acute elevation of their ALC at 50, 50 and 36 days
after transplant, concurrent with a rapid decline in donor
chimerism (see Table 1). Patients received alemtuzumab 0.8
e 1.0mg/kg over the course of 3-5 days, resulting in expected
lymphopenia which corresponded with improving donor
chimerism by the end of the ﬁrst week of therapy. First 2
patients have continued to have full donor chimerism
(>99% donor) for > 3 months. Patient # 3 although showed
improving chimerism (up to 81.4%), did not recover from
secondary graft failure and went on to receive second
transplant from a 6/8 HLA matched parent donor. After
initial engraftment of 100%, she again had an acuteusing a Miltenyi Clini MACS device
0 Day + 51 Day + 52 Day + 53 Day + 54 Day + 55 Day + 59
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82 100 100 100 100
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73 79 91 94 99 100
6 Day + 40 Day + 43 Day + 50
870
32.6 53.1 81.4
7 Day + 18 Day + 19 Day + 23
530 260 0
96 99 100
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to 85%. This time alemtuzumab was used promptly, leading
to successful outcome (Table 1).
Conclusion: In patients with Fanconi Anemia undergoing
transplant, the development of mixed chimerismmay be due
to incomplete lympho-depletion and return of recipient
lymphocytes. In these cases, prompt and aggressive
lymphoid depleting therapy is warranted to prevent graft
rejection.262
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Background: NF-kappa B essential modulator (NEMO) is an
important activator ofNF-kappaB,which regulatesnumerous
genes involved in immune responses and ectodermal devel-
opment. Hypomorphic mutations in NEMO have been asso-
ciatedwith a spectrumof disorder such as X linked anhidrotic
ectodermal dysplasia with immunodeﬁciency (XL-EDA-ID),
X- liked immunodeﬁciencywithout ectodermal dysplasia and
isolated susceptibility to atypical mycobacteria. Currently,
allogeneic hematopoietic cell transplantation (HCT) is the
only curative therapy for patients with NEMO defects.
However, there are only fewcase reports of successful HCT for
this disorder. Herewe reportour experience of allogeneicHCT
for patients with NEMO defect.
Methods: We retrospectively analyzed the outcomes of 4
patients with NEMO defect who had undergone allogeneic
HCT between January 2005 and September 2012 in our
institution. Hypomorphic mutations in NEMO were identi-
ﬁed in all 4 patients. Three had XL-EDA-ID and one had X-
liked immunodeﬁciency without ectodermal dysplasia. Prior
to transplant all of them had recurrent bacterial infections
and two of them had disseminated atypical mycobacterial
infection. Autoimmune hemolytic anemia was noted in two
patients. The median age at transplantation was 10.5 years
(range: 3.3-18.2). All of them underwent myeloablative
preparative regimen consisting of busulfan, cyclophospha-
mide, and ATG, and busulfan kinetics were used to dose
busulfan. Two patients received matched (8/8) unrelated
donor (URD) bone marrow transplant and two received
single locus mismatch (7/8) URD bone marrow transplant. In
all patients cyclosporine and prednisone was used as GvHD
prophylaxis.
Result: Overall survival was 75% (3/4) at a median follow-up
of 59 months post-transplant (range: 12 -70). The median
time for neutrophil engraftment was 12.5 days (range: 11-
15). Grade II to III acute GVHD developed in two patients and
one patient developed chronic skin GVHD. Mixed donor
chimerism was noted in one patient needing stem cell boost
4 years after HCT. Death in one patient was due to HSV
pneumonitis and disseminated mycobacterial infection with
multi-organ failure. All surviving patients immune recon-
stituted with normal lymphocyte subpopulation, normal
distribution of CD45RA/RO, normal NK cell function and
mitogen response. Two patients are currently off immuno-
globulin replacement with good speciﬁc antibody response
to both protein and polysaccharide antigens.
Conclusion: HCT is effective in correction of innate and
adaptive immune defects associated with NEMO deﬁciency.Further follow-up and larger multi-institutional studies are
needed to better understand the role of HCT in this disorder.263
Autologous Hematopoietic Stem Cell Transplantation in
a Single Pediatric Center
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After the ﬁrst ﬁve years workingwe evaluate the results of
Autologous Stem Cell Transplantation (ASCT) performed
between2007and2012, a total of 25ASCT,16neuroblastomas,
6HodgkinDiseases,1 LBCL,1 AML,1 PNET.Median agewas 7.2
years, 13 females, 12 males. Conditioning regimens were 17
CEM, 5 BU/MEL, 3 BEAM. Stem cell sourcewas 21 PBSC, 2 PBSC
+BM,2BM.ThemedianMNCandCD34 infusedwere5.3x108/
kg and 4.21 x 106/kg. Hematological recovery median time
was 11 days for neutrophils 12 days for platelets. Hospitali-
zation median time was 34 days, two patients (SDRA- graft
syndrome and gastrointestinal bleeding) required transfer to
the intensive care unit, both of them improved and dis-
charged. One hundred days mortality was 12% (3 patients) all
for relapseof theunderlyingdisease.Of a total of 25patients, 9
patients (36%) have died, all cases because of disease relapse.
These data show a very low transplant related mortality as
expected for ASCT, and demonstrate that autologous trans-
plantation in pediatric patients can be safely and effectively
performed indeveloping countrieswith results comparable to
those obtained in developed countries. Our goal in the future
is to assess the long termeffects on survivors and showsimilar
results in allogeneic related and unrelated transplants
currently under evaluation.264
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Introduction: Allogeneic hematopoietic stem cell trans-
plantation (HSCT) for malignant disorders is complicated by
the risk of early and late treatment related toxicities.
Reduced toxicity conditioning (RTC) regimens using
Busulfan/Fludarabine (Bu/Flu) +/- 400Gy of Total Body Irra-
diation (TBI) were designed to lower the risk of these
complications while achieving similar outcomes to the
standard myeloablative conditioning (sMAC) with Busulfan/
Cyclophosphamide (Bu/Cy) or 1200 Gy TBI/ Cyclophospha-
mide (TBI/Cy). Methods We compared outcomes of children
conditioned with sMAC versus RTC pre-HSCT between Jan
2008 and Dec 2011. In both regimens, the total dose of Buwas
adjusted to target an AUC of 16000 mM*min. Long term
outcome analysis included assessment of change in pulmo-
nary function test (PFT), cardiac function, thyroid function
and growth from baseline. Patients with GVHD of the lung
were excluded for assessing pulmonary function. Results
Sixty seven patients with AML/MDS (n¼29), ALL (n¼ 32),
